CENTRISA 21 TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

NORGESTIMATE; ETHINYL ESTRADIOL; NORGESTIMATE; ETHINYL ESTRADIOL; NORGESTIMATE; ETHINYL ESTRADIOL

から入手可能:

PATRIOT A DIVISION OF JANSSEN INC

ATCコード:

G03AB11

INN（国際名）:

NORGESTIMATE AND ESTROGEN

投薬量:

0.180MG; 0.035MG; 0.215MG; 0.035MG; 0.250MG; 0.035MG

医薬品形態:

TABLET

構図:

NORGESTIMATE 0.180MG; ETHINYL ESTRADIOL 0.035MG; NORGESTIMATE 0.215MG; ETHINYL ESTRADIOL 0.035MG; NORGESTIMATE 0.250MG; ETHINYL ESTRADIOL 0.035MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

CONTRACEPTIVES

製品概要:

Active ingredient group (AIG) number: 0636783002; AHFS:

認証ステータス:

CANCELLED PRE MARKET

承認日:

2017-08-03

製品の特徴

_165350.doc _
_ _
_Page 1 of 51 _
PRODUCT MONOGRAPH
PR
CENTRISA
™
21 AND
PR
CENTRISA
™
28
norgestimate and ethinyl estradiol tablets, House Std.
0.180 mg norgestimate and 0.035 mg ethinyl estradiol Tablets
0.215 mg norgestimate and 0.035 mg ethinyl estradiol Tablets
0.250 mg norgestimate and 0.035 mg ethinyl estradiol Tablets
Oral Contraceptive
Patriot, a Division of Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.patriot-canada.ca
Date of Preparation:
August 19, 2013
SUBMISSION CONTROL NO.: 165350
All trademarks used under license.
© 2013 Patriot, a Division of Janssen Inc.
_165350.doc _
_ _
_Page 2 of 51 _
PRODUCT MONOGRAPH
PR
CENTRISA
™
21 AND
PR
CENTRISA
™
28
norgestimate and ethinyl estradiol tablets, House Std.
0.180 mg norgestimate and 0.035 mg ethinyl estradiol Tablets
0.215 mg norgestimate and 0.035 mg ethinyl estradiol Tablets
0.250 mg norgestimate and 0.035 mg ethinyl estradiol Tablets
PHARMACOLOGICAL CLASSIFICATION
Synthetic steroidal combination oral contraceptive.
CLINICAL PHARMACOLOGY
The primary mechanism of action of CENTRISA
™
Tablets is an inhibition of ovulation.
Additionally, other effects caused by the treatment (for example,
alteration of the endometrium
and the thickening of the cervical mucus) appear to interfere with
implantation and conception.
INDICATIONS AND CLINICAL USE
CENTRISA
™
Tablets are indicated for conception control.
CENTRISA
™
Tablets are indicated for the treatment of moderate acne vulgaris in
females who
have no known contraindications to oral contraceptive therapy.
CONTRAINDICATIONS
1.
History of or actual thrombophlebitis or thromboembolic disorders.
2.
Known thrombophilic conditions.
3.
History of or actual cerebrovascular disorders.
4.
History of or actual myocardial infarction or coronary arterial
disease.
5.
Active liver disease or history of or actual benign or malignant liver
tumours.
6.
Known or suspected carcinoma of the breast.
7.
Known or suspected estrogen-dependent neoplasia.
8.
Undiagnosed abnormal vaginal bleeding.
9.
Any ocula